VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SKWDSkyward Specialty Insurance Group, Inc.
$59.19$2.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSKWDFinancials

Skyward Specialty Insurance Group, Inc. (SKWD) Financials

7Y historyFree accessUpdated daily

The company achieved a 19.7% year-over-year revenue expansion in 2026Q1 while maintaining a structurally sound 84.3% combined ratio, signaling effective pricing power in its specialty segments.

SKWD Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'13
Revenue1.55B1.41B1.15B895.4M636.4M535.82M447.89M218.24M
Revenue Growth %22.89%23.18%28.17%40.7%18.77%19.63%105.23%-
Medical Costs & Claims1.02B795.02M819.78M623.75M468.21M401.47M399.15M0
Medical Cost Ratio %66.24%56.24%71.43%69.66%73.57%74.93%89.12%0%
Gross Profit484.81M622.11M327.89M271.65M168.2M134.35M48.73M218.24M
Gross Margin %31.36%44.01%28.57%30.34%26.43%25.07%10.88%100%
Gross Profit Growth %-89.73%20.7%61.51%25.19%175.68%-77.67%-
Operating Expenses233.49M405.68M175.15M161.55M118.42M86.04M143.27M197.19M
OpEx / Revenue %15.1%28.7%15.26%18.04%18.61%16.06%31.99%90.36%
Depreciation & Amortization10.14M3.54M3.36M3.89M4.1M5.6M5.99M0
Combined Ratio %81.34%84.94%86.69%87.7%92.18%90.98%121.11%90.36%
Operating Income237.82M216.42M152.74M110.1M49.78M48.31M-94.53M21.05M
Operating Margin %15.38%15.31%13.31%12.3%7.82%9.02%-21.11%9.64%
Operating Income Growth %-41.7%38.73%121.16%3.05%151.1%-549.17%-
EBITDA248.04M219.96M156.1M113.99M53.88M53.91M-88.55M16.74M
EBITDA Margin %16.05%15.56%13.6%12.73%8.47%10.06%-19.77%7.67%
Interest Expense13.8M7.92M9.5M10.02M6.41M4.62M5.53M0
Non-Operating Income-13.8M-7.92M-9.5M-10.02M-6.41M-4.62M-5.53M4.31M
Pretax Income227.06M216.42M152.74M110.1M49.78M48.31M-94.53M16.74M
Pretax Margin %14.69%15.31%13.31%12.3%7.82%9.02%-21.11%7.67%
Income Tax49.36M46.4M33.91M24.12M10.39M9.99M-19.89M5.86M
Effective Tax Rate %21.74%21.44%22.2%21.91%20.86%20.68%21.04%35%
Net Income184.76M170.03M118.83M85.98M39.4M38.32M-74.64M10.88M
Net Margin %11.95%12.03%10.35%9.6%6.19%7.15%-16.67%4.98%
Net Income Growth %40%43.09%38.2%118.26%2.82%151.33%-786.11%-
EPS (Diluted)4.414.072.872.241.051.18-2.140.29
EPS Growth %35.85%41.81%28.13%113.33%-11.02%155.14%-837.93%-
EPS (Basic)-4.212.962.341.051.21-1.990.29
Diluted Shares Outstanding41.87M41.87M41.38M38.32M37.6M32.47M34.93M37.6M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Social inflation litigation exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Sustained Premium Growth Amid Hardening

As reported in financial statements, Skyward Specialty achieved a 19.7% year-over-year revenue increase in 2026Q1, demonstrating consistent top-line expansion that suggests the company is successfully leveraging current market pricing power to capture share within its specialized, non-commoditized niche underwriting segments across the United States.

The consistent double-digit growth trajectory indicates that the firm's focus on underserved specialty markets remains a potent driver of volume. Investors should monitor whether this rapid expansion persists without compromising the quality of the underlying risk selection as the competitive landscape evolves.

Underwriting Profitability Remains Structurally Sound

Based on the company's reported figures, the combined ratio of 84.3% in 2026Q1 highlights a robust underwriting margin, reflecting a disciplined approach to claims management that appears to effectively insulate the bottom line from the volatility often seen in broader commercial insurance market cycles.

Maintaining a combined ratio consistently below 90% suggests that the company's specialized underwriting talent is successfully pricing risk above the expected loss costs. This performance implies that the firm is not currently reliant on investment income to achieve overall profitability, which provides a significant buffer against potential market downturns.

Operational Resilience Following 2024 Volatility

According to historical income data, the firm successfully navigated a significant earnings dip in 2024Q4, where the combined ratio spiked to 93.9%, by rapidly returning to a sub-85% ratio in subsequent quarters, signaling an effective recovery from localized underwriting pressures or potential reserve adjustments.

The sharp rebound from the 2024Q4 earnings trough suggests that the company's operational infrastructure is capable of absorbing short-term shocks without long-term impairment to its profitability profile. This recovery warrants further investigation into whether the 2024Q4 event was a structural anomaly or a recurring risk inherent in the company's specific liability lines.

Litigation Tailwinds and Reserve Adequacy

While current underwriting margins appear strong, analysis of the loss ratio trends suggests that rising social inflation and litigation costs in casualty lines may pose a latent risk to future reserve adequacy, as indicated by the fluctuations in loss ratios observed over the last ten quarters.

Investors should remain cautious regarding the potential for future reserve strengthening, which could mask underlying underwriting deterioration if loss trends in commercial auto and professional liability continue to accelerate. The current profitability may be partially dependent on favorable reserve development that could prove unsustainable if litigation severity trends persist.

SKWD — Frequently Asked Questions

Quick answers to the most common questions about buying SKWD stock.

What was Skyward Specialty Insurance Group, Inc.'s (SKWD) revenue in 2025?

For fiscal year 2025, Skyward Specialty Insurance Group, Inc. (SKWD) reported total revenue of $1.41B. This represents a 547.8% increase compared to $218.2M in 2013.

Is Skyward Specialty Insurance Group, Inc. (SKWD) profitable?

Skyward Specialty Insurance Group, Inc. (SKWD) is profitable, generating $170.0M in net income for the fiscal year ending 2025 with a net profit margin of 12.0%.

What is Skyward Specialty Insurance Group, Inc.'s operating profit margin?

Skyward Specialty Insurance Group, Inc. (SKWD) reported an operating income of $216.4M, resulting in an operating profit margin of 15.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Skyward Specialty Insurance Group, Inc.'s gross profit and gross margin?

Skyward Specialty Insurance Group, Inc. (SKWD) generated $622.1M in gross profit for the year, representing a gross profit margin of 44.0%. This demonstrates the company's core pricing power and production efficiency.